At the most recent follow-up, subjects in the study showed a mean improvement from baseline in visual acuity of + 23 letters in the treated eye. The untreated control eyes did not show meaningful ...

LONDON, July 16, 2019 /PRNewswire/ -- ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announced that it has expanded its intellectual ...

Benitec Biopharma (ASX: BLT; OTCPK: BTEBD) is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi ...

ReNeuron will discontinue, out-license or dispose of all its legacy assets. (DON'T USE) Iain Ross has made an immediate mark on ReNeuron, overseeing a restructuring to reduce the British biotech’s ...

Angel Biotech (LON:ABH), the biopharmaceutical contract manufacturer, has signed a revised, longer-term contract with fellow AIM company Reneuron (LON:RENE) that will see it provide development and ...

SYDNEY, June 22, 2015 /PRNewswire/ -- Benitec Biopharma (ASX: BLT; OTCPK: BTEBD) is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery ...

Patient recruitment for trial with expanded neural stem cell product will begin in April. Stem cell therapeutics company ReNeuron raised about £4.7 million (almost $7.3 million) before expenses in a ...

Dr David Howard, Senior Postdoctoral Research Associate working on the project using the IZON size exclusion chromatography system for exosome purification. ReNeuron Group Limited, a leading UK ...

Acquisition will help firm advance its type 1 diabetes therapy. ReNeuron reported plans to buy the business assets of AmCyte, a development-stage cell therapy company, in a transaction worth about $4 ...

ReNeuron receives final regulatory approval to commence landmark stroke clinical trial in UK. Guildford, UK, 10 February 2010: ReNeuron Group plc (LSE: RENE.L) today announces that the UK Gene Therapy ...